146 related articles for article (PubMed ID: 38672596)
1. Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [
Einspieler H; Kluge K; Haberl D; Schatz K; Nics L; Schmitl S; Geist BK; Spielvogel CP; Grubmüller B; Baltzer PAT; Kramer G; Shariat SF; Hacker M; Rasul S
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672596
[TBL] [Abstract][Full Text] [Related]
2. Impact of [
Groener D; Wichert J; Adams M; Mader N; Klimek K; Nguyen Ngoc C; Baumgarten J; Happel C; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568694
[TBL] [Abstract][Full Text] [Related]
3. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
6. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
7. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
8. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
9. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246
[No Abstract] [Full Text] [Related]
10. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
11. Renal outcomes of radioligand therapy: experience of
Gallyamov M; Meyrick D; Barley J; Lenzo N
Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
[TBL] [Abstract][Full Text] [Related]
12. Total Tumor Volume on
Unterrainer LM; Beyer L; Zacherl MJ; Gildehaus FJ; Todica A; Kunte SC; Holzgreve A; Sheikh GT; Herlemann A; Casuscelli J; Brendel M; Albert NL; Wenter V; Schmidt-Hegemann NS; Kunz WG; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ilhan H; Unterrainer M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625683
[TBL] [Abstract][Full Text] [Related]
13. Response Assessment and Prediction of Progression-Free Survival by
Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
[TBL] [Abstract][Full Text] [Related]
14. Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [
Fernández R; Soza-Ried C; Iagaru A; Stephens A; Müller A; Schieferstein H; Sandoval C; Amaral H; Kramer V
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201600
[TBL] [Abstract][Full Text] [Related]
15. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
16. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
17. Intermittent Radioligand Therapy with
Mader N; Schoeler C; Pezeshkpour N; Klimek K; Groener D; Happel C; Tselis N; Mandel P; Grünwald F; Sabet A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760574
[No Abstract] [Full Text] [Related]
18. Extended therapy with [
Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
[TBL] [Abstract][Full Text] [Related]
19. Comparison of novel PSMA-targeting [
Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38658392
[TBL] [Abstract][Full Text] [Related]
20. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
Laarhuis BI; Janssen MJR; Simons M; van Kalmthout LWM; van der Doelen MJ; Peters SMB; Westdorp H; van Oort IM; Litjens G; Gotthardt M; Nagarajah J; Mehra N; Privé BM
Clin Genitourin Cancer; 2023 Oct; 21(5):e352-e361. PubMed ID: 37164814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
